2Q2026: Sustaining Growth,
Profitability and Financial Strength
A quick view of PR9’s key financial and operating indicators, reflecting the company’s revenue scale, profitability, balance sheet strength, and shareholder return profile.
Financial Performance
Total Revenue
Supported by higher IPD revenue and steady international demand.
Net Profit
Net profit and NPM, reflecting disciplined cost control.
ROE
Supported by a strong equity base and efficient use of assets.
International Growth
Demand for world-class healthcare in Thailand is growing PR9: Built on Trust, Growing with Specialty Care
A trusted destination for international patients
Complex-care capability drives earnings quality
A strong balance sheet funds the expansion
PR9 - Strategic Plan 2026
Driving sustainable growth by delivering medical center excellence and seamless experiences through efficient collaboration, enabled by digital transformation.
Global Standard
World-class Hospitality
Efficiency with Collaboration
Digital Transformation
Why Invest in Praram 9 Hospital
A specialized healthcare platform with growth potential across case mix, international patients, and long-term returns. PR9’s investment profile is supported by specialized medical capabilities, a growing international patient base, and disciplined operations that support sustainable long-term growth.
Built for higher-value healthcare demand
PR9 is moving beyond volume-driven growth by strengthening specialized services and medical capabilities that support long-term earnings quality.
Capturing regional healthcare opportunities
A growing international patient base gives PR9 a broader growth platform and supports the company’s ambition to become a trusted regional healthcare destination.
Strong fundamentals through market cycles
The company’s margin foundation remains underpinned by operational discipline, service quality, and a focused healthcare model.
Growth with financial discipline
PR9 balances expansion with prudent capital management, creating room for sustainable growth and shareholder returns over time.
Stay informed with our latest stock performance,
SET announcements, and key investor documents.
SET Announcements
View All
Investor FAQ
Find answers to common investor questions about our business, performance, and shareholder information.
The Company provides medical and healthcare services under the name "Praram 9 Hospital" through a single hospital. Operations commenced in 1992, and the Hospital currently has a total registered bed capacity of 204 beds. The Company focuses on specialized medicine and the treatment of difficult and complex diseases under the vision of becoming the "Most Trusted Hospital", offering quality services at cost-effective and reasonable rates (Value for Money Services).
The Company is positioned as a specialized hospital for difficult and complex diseases, particularly through nationally recognized Kidney and Transplant Institute, while offering Value for Money compared with internationally recognized treatment quality. The Hospital has maintained JCI accreditation continuously since 2010 and was ranked among Thailand's Top 10 leading hospitals in Newsweek's World's Best Hospitals 2025. This positioning means that the Company does not compete primarily on price with general hospitals and does not bear the administrative costs of operating a large hospital network.
Praram 9 Hospital has five Centers of Excellence, as follows:
- Kidney and Transplant Institute
- Cardiovascular Institute
- Neuroscience Center
- Orthopedic Center
- Minimally Invasive Surgery (MIS) Center
All five centers operate under the Global Standard strategy and focus on vital organs and complex diseases. They are key drivers of the Company's Case Intensity and revenue per case.
In 2025, international patient revenue grew by 73% and accounted for 26% of hospital revenue, with fly-in patients from the Middle East as the main growth driver. The Company recognizes the risks associated with concentration and regional uncertainty and is therefore planning to diversify the market base into new target countries. Thai patients nevertheless remain the Company's primary revenue base, accounting for approximately 74% of hospital revenue, which helps limit the impact if any single market slows.
The Company is expanding Thai patient base through proactive cooperation with insurers and corporate contract partners, as demonstrated by the more-than-doubling of Corporate Contract revenue in 2025. This is being pursued alongside the launch of new services targeting younger generations, in addition to the existing base of elderly patients and patients with complex diseases, as well as proactive brand communications in Thailand and overseas.
The Company manages capacity by increasing value per case rather than relying solely on an increase in the number of beds. It continues to invest in ICU/CCU facilities, medical equipment for complex treatments, premium patient wards, and the renovation and expansion of service areas to accommodate rising patient volumes. Treatment of complex diseases generates higher revenue per patient day than general treatment, allowing revenue to grow even with a stable bed count, as reflected in 2025 IPD revenue growth of 26.8%, driven by both patient days and average revenue per patient day.
Questions, shareholders can contact the dedicated Investor Relations department.
